Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | 5-azacytidine | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | chronic myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, western blot, RNAi etc. |
| Sample | chronic myeloid leukemia tissues, cell lines (KCL22 and K562) |
| Expression Pattern | down-regulated |
| Function Description | We found that MEG3 and PTEN expression were downregulated, whereas, MDM2, DNMT1 and miR-21 were up-regulated in the accelerated and blast phases of CML. demethylation drugs might also have potential clinical application in treating CML blast crisis. Due to the effect on MEG3 and miR-21, 5-azacytidine may be a possible new therapeutic option for CML blast crisis |
| Pubmed ID | 29772439 |
| Year | 2018 |
| Title | Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21 |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for chronic myeloid leukemia | OMIM COSMIC |